Combining anti-cancer therapies with orthogonal modes of action, such as direct cytotoxicity and immunostimulatory, hold promise for expanding clinical benefit to patients with metastatic disease. | An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer